Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

After hours: March 14 at 7:57:35 PM EDT Loading Chart for AMGN ...

Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 23% SPDR S&P 500 UCITS ETF - USD DIS 23% ...

After hours: March 13 at 7:20:24 PM EDT ...

After hours: 13 March at 7:20:24 pm GMT-4 Loading Chart for AMGN ...

1 In 2024, Dr. Kelly’s team reported the first-in-human study of Xaluritamig monotherapy dose exploration for patients with mCRPC, primarily taxane pretreated. 2 There were 97 patients that received ...